Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Moxifloxacin, Azithromycin, and Doxycycline in Stable COPD
NCT01398072Phase 3Unknown
- Sponsor
- University College London
- Start
- Dec 2011
- Primary completion
- Jan 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of moxifloxacin, azithromycin and doxycycline in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by University College London. Primary endpoint: Reduction in the concentration of lower airway bacteria at 14 weeks. Status: unknown.
02
Drugs
moxifloxacinazithromycindoxycycline
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01398072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01398072.